Abstract

Influenza virus has the potential for being one of the deadliest viruses, as we know from the pandemic’s history. The influenza virus, with a constantly mutating genome, is becoming resistant to existing antiviral drugs and vaccines. For that reason, there is an urgent need for developing new therapeutics and therapies. Despite the fact that a new generation of universal vaccines or anti-influenza drugs are being developed, the perfect remedy has still not been found. In this review, various strategies for using nanoparticles (NPs) to defeat influenza virus infections are presented. Several categories of NP applications are highlighted: NPs as immuno-inducing vaccines, NPs used in gene silencing approaches, bare NPs influencing influenza virus life cycle and the use of NPs for drug delivery. This rapidly growing field of anti-influenza methods based on nanotechnology is very promising. Although profound research must be conducted to fully understand and control the potential side effects of the new generation of antivirals, the presented and discussed studies show that nanotechnology methods can effectively induce the immune responses or inhibit influenza virus activity both in vitro and in vivo. Moreover, with its variety of modification possibilities, nanotechnology has great potential for applications and may be helpful not only in anti-influenza but also in the general antiviral approaches.

Highlights

  • Influenza virus is a member of the Orthomyxovirade family of viruses [1]

  • This review focuses on nanotechnology trends towards the facilitation of existing anti-influenza strategies and new methodologies applying NPs against influenza viruses

  • We present different strategies of using NPs to fight influenza virus infection: NPs as immunity-inducing vaccines, NPs used in gene silencing approaches, the use of NPs for drug delivery, and bare NPs which exhibit anti-influenza properties (Table 1)

Read more

Summary

Introduction

Four influenza viruses can be distinguished: A, B, C (known for being human-infectious) and D (so far unconfirmed for being human-threatening) [2]. RNAs along with viral proteins form eight viral ribonucleoprotein (vRNP) complexes. Each vRNP consists of the viral RNA segment bound to viral heterotrimeric RNA-dependent RNA polymerase (RdRp) and coated with nucleoproteins (NP). The influenza virus’ life cycle is entirely dependent on both RNA and viral polymerase. The eight segments encode at least 16 proteins, including through alternative splicing and translation initiation [4]. These proteins include nucleoprotein, hemagglutinin (HA), neuraminidase (NA), matrix protein 1 and Pathogens 2020, 9, 1020; doi:10.3390/pathogens9121020 www.mdpi.com/journal/pathogens. 2 (M1, M2), nuclear export protein (NEP), subunits of RNA-dependent RNA polymerase complex. PB2 and PA), well two non-structural proteins: PB1-F2 and NS1 (Figure 1)

Scheme of influenza
Influenza
Influenza Virus Inhibition Strategies Based on the Use of Nanoparticles
Schematic
Inactivated Influenza Virus Strategy Based on NPs Delivery
Nanotechnology in Gene Silencing Strategies
Antisense
DNAzymes Strategy Based on NPs Delivery
Bare Nanoparticles Antiviral Strategy
Nanotechnology in Delivery of Drugs Targeting Proteins
Findings
Conclusions

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.